ACADIA Pharmaceuticals Inc. (ACAD)

24.37
0.63 2.65
NASDAQ
Prev Close 23.74
Open 23.74
Day Low/High 23.53 / 24.78
52 Wk Low/High 12.77 / 27.77
Volume 1.47M
Exchange NASDAQ
Shares Outstanding 143.88B
Market Cap 3.39B
Div & Yield N.A. (N.A)
ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia

ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of ADVANCE, a...

Acadia Shares Soar as Nuplazid Sales Easily Top Estimates

Acadia Shares Soar as Nuplazid Sales Easily Top Estimates

Acadia reported sales of its treatment for hallucinations associated with Parkinson's disease that more than doubled estimates in the third quarter.

Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More

Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More

Here are Tuesday's top research calls, including downgrades for Bank of America, Depomed, Hertz and AT&T.

ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results

ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

Cisco, Allergan, Facebook: Doug Kass' Views

Cisco, Allergan, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.

ACADIA Pharmaceuticals Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia

ACADIA Pharmaceuticals Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of ENHANCE-1, a...

Small Biotechs on My Shopping List

Small Biotechs on My Shopping List

These small-caps are woefully undervalued after getting shellacked in October.

ACADIA Pharmaceuticals To Announce Third Quarter 2016 Financial Results On November 7, 2016

ACADIA Pharmaceuticals To Announce Third Quarter 2016 Financial Results On November 7, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Initiates Phase II Study Of Pimavanserin In Alzheimer's Disease Agitation

ACADIA Pharmaceuticals Initiates Phase II Study Of Pimavanserin In Alzheimer's Disease Agitation

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of SERENE, a...

Schlumberger, Amazon, Apple: Doug Kass' Views

Schlumberger, Amazon, Apple: Doug Kass' Views

Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.

Biotech Bargain Bin Bursts With Bounty

Biotech Bargain Bin Bursts With Bounty

This sector is one of the few areas of the market where you'll find myriad compelling values.

ACADIA Pharmaceuticals Receives California Life Sciences Association's 2016 Pantheon DiNA Award For Outstanding Therapeutic Product For NUPLAZID™

ACADIA Pharmaceuticals Receives California Life Sciences Association's 2016 Pantheon DiNA Award For Outstanding Therapeutic Product For NUPLAZID™

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders,...

J.C.Penney, Wells Fargo, Deutsche Bank: Doug Kass' Views

J.C.Penney, Wells Fargo, Deutsche Bank: Doug Kass' Views

Doug Kass shares his thoughts on the banks and looks back on 20 years with TheStreet.

ACADIA Pharmaceuticals To Present At The Ladenburg Thalmann 2016 Healthcare Conference On September 27, 2016

ACADIA Pharmaceuticals To Present At The Ladenburg Thalmann 2016 Healthcare Conference On September 27, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Sponsors National Parkinson Foundation's Caregiver Summit

ACADIA Pharmaceuticals Sponsors National Parkinson Foundation's Caregiver Summit

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders, is...

These 5 Biotech Stocks Are Ready for a Volatility Break

These 5 Biotech Stocks Are Ready for a Volatility Break

The squeeze is on these stocks, and they are poised for volatile moves.

Don't Be Fooled, There's Still Complacency Here

We should rebound and then come back down again.

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These stocks are within range of triggering big breakout trades.

ACADIA Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference On September 12, 2016

ACADIA Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference On September 12, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Todd S. Young, Executive Vice President, Chief Financial Officer Of ACADIA Pharmaceuticals (Photo: Business Wire)

Todd S. Young, Executive Vice President, Chief Financial Officer Of ACADIA Pharmaceuticals (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

ACADIA Pharmaceuticals Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

Tracking Bullish and Bearish Reversals

Tracking Bullish and Bearish Reversals

These stocks have made U-turns in the past week.

Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta

Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

ACADIA Pharmaceuticals Prices Public Offering Of Common Stock

ACADIA Pharmaceuticals Prices Public Offering Of Common Stock

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

Highlighted Post-Market Laggard: ACADIA Pharmaceuticals (ACAD)

Highlighted Post-Market Laggard: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a post-market laggard candidate

ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results

ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

ACADIA Pharmaceuticals To Announce Second Quarter 2016 Financial Results On August 4, 2016

ACADIA Pharmaceuticals To Announce Second Quarter 2016 Financial Results On August 4, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...